"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.
Pedtrace Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Pedtrace (zinc, copper, manganese and chromium intravenous solution) is a source of minerals used for total parenteral nutrition (TPN) in pediatric patients. Side effects of Pedtrace are uncommon; consult your doctor.
Dose of Pedtrace is based on the child's body weight. Pedtrace may interact with other drugs. Tell your doctor all medications and supplements your child uses. This product is intended for pediatric patients and is unlikely to be used during pregnancy or while breastfeeding; consult your doctor.
Our Pedtrace (zinc, copper, manganese and chromium intravenous solution) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Pedtrace FDA Prescribing Information: Side Effects
The amounts of zinc, copper, chromium and manganese in Pedtrace (zinc, copper, manganese and chromium intravenous solution) ®-4 are very small and toxicity symptoms due to these trace elements at suggested dosage levels are considered unlikely to occur.
DRUG ABUSE AND DEPENDENCE
Read the entire FDA prescribing information for Pedtrace (Zinc, Copper, Manganese and Chromium Intravenous Solution)
Additional Pedtrace Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.